GlassScriptPhysician profile
Gregory Kirk Barron
NPI 1871859801
$4,211.28
in general payments reported to CMS, 2019-2025
25 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $376 · 2021: $748 · 2022: $996 · 2023: $362 · 2024: $266 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.90 | 2019-2024 | |
| Glaxosmithkline, LLC. | $812.96 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $628.32 | 2019-2025 | |
| Pfizer INC. | $421.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $233.72 | 2019-2025 | Orencia |
| Amgen INC. | $232.02 | 2019-2025 | Tavneos, Amjevita, Avsola |
| Horizon Therapeutics Plc | $174.60 | 2019-2023 | Krystexxa |
| Kiniksa Pharmaceuticals International, Plc | $103.25 | 2024 | Arcalyst |
| Genentech USA, INC. | $89.48 | 2020-2023 | Actemra |
| Janssen Biotech, INC. | $87.55 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $82.35 | 2022-2025 | Purified Cortrophin Gel |
| Zimmer Biomet Holdings, INC. | $70.94 | 2019 | |
| Mallinckrodt Hospital Products INC. | $69.07 | 2023-2024 | Acthar |
| Sanofi-Aventis U.S. LLC | $57.35 | 2019 | |
| Lemaitre Vascular, INC. | $35.35 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $32.43 | 2025 | Uptravi, Opsumit |
| Antares Pharma, INC. | $32.23 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $20.24 | 2019 | |
| Hikma Pharmaceuticals USA | $20.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.90 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.86 | 2023 | Arcalyst |
| Organon LLC | $16.53 | 2025 | Hadlima |
| Depuy Synthes Sales INC. | $16.43 | 2023 | Orthovisc, Monovisc |
| Ferring Pharmaceuticals INC. | $15.44 | 2019 | |
| Genzyme Corporation | $14.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.